Suche
Mein Konto
Radiometer strengthens its global immunoassay business in Turku
Radiometer announces that it will purchase its current facility in Turku and expand the site's manufacturing and research and development capabilities, a move that will expand its global immunoassay business. By transitioning from a lease to ownership of the site, Radiometer strengthens its global manufacturing and development activities to accommodate the future growth of its global immunoassay business. “We are securing additional space to double production and R&D space in Turku in the coming years to accommodate Radiometer Turku’s future growth and maintain a leading role in assay development,” says Sebastian Kräemer, General Manager of…
Radiometer strengthens its global immunoassay business in Turku
Radiometer announces that it will purchase its current facility in Turku and expand the site's manufacturing and research and development capabilities, a move that will expand its global immunoassay business.
By transitioning from a lease to ownership of the site, Radiometer strengthens its global manufacturing and development activities to accommodate the future growth of its global immunoassay business.
“We are securing additional space to double the production and R&D space in Turku in the coming years to accommodate Radiometer Turku’s future growth and maintain a leading role in assay development,” says Sebastian Kräemer, General Manager of Radiometer Turku Oy.
Sanna Wallenborg, vice president and general manager of Radiometer's immunoassay business unit, added: "This is a very important milestone for our overall immunoassay business and ensures we can meet increasing customer demands and execute on our growth strategy."
Radiometer was founded in Denmark in 1935 and introduced the world's first commercially available blood gas analyzer. The company's products and solutions provide information on critical parameters in acute care and thus support the diagnosis of critically ill patients. Radiometer Turku Oy develops, designs and produces immunoassay test kits for immunoassay testing, including cardiac and infection biomarkers.
After investing in a new production line in Turku in 2021, the acquisition of the site is part of Radiometer's multi-million dollar investment to secure the space required to support their growth strategy. Half of the building has been rented and occupied by Radiometer for years. “The site will be equipped with the latest production technologies, including artificial intelligence and IoT, and I look forward to an exciting future as we embark on this new chapter of our growth journey,” concludes Sebastian.
CBRE and Hannes Snellman acted as advisors to Radiometer on the acquisition of the building.
.